RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Niederst, Matthew J., Sequist, Lecia V., Poirier, John T., Mermel, Craig H., Lockerman, Elizabeth L., Garcia, Angel R., Katayama, Ryohei, Costa, Carlotta +19 more·2015·Nature Communications
DOI 10.1038/ncomms7377

Cited by (655)

Items 501–600 of 655

  1. Exploring the Molecular Players behind the Potentiation of Chemotherapy Effects by Durvalumab in Lung Adenocarcinoma Cell Lines
    M. Saar, Jana Jaal, Alvin Meltsov, Tõnis Laasfeld, Helen Lust, Sergo Kasvandik, Darja Lavõgina · 2023 · Pharmaceutics
  2. Combined small cell lung cancer: current progress and unmet needs.
    Chen Zeng, Guihuan Qiu, Xiaohong Xie, Ting Liu, Ziyao Chen, Xiaoyi Zhang, Wensheng Zhou, Xinqing Lin, Zhanhong Xie, Yinyin Qin et al. · 2023 · PubMed Central
  3. Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report
    Victor C. Kok, Chien-Kuan Lee, Yu-Hsin Chiang, Ming-Chih Wang, Yen-Te Lu, Chiu-Chun Cherng, Pei-Yu Alison Lee, Kebin Wang · 2021 · Frontiers in Oncology
  4. Introduction
    Harun Patel, Rahul H. Pawara, Sanjay Javerilal Surana · 2019 · Elsevier eBooks
  5. Inhibition of EGFR pathway promotes the cytotoxicity of ABT-263 in human leukemia K562 cells by blocking MCL1 upregulation
    Yuan‐Chin Lee, Liangjun Wang, Chia‐Hui Huang, Jing‐Ting Chiou, Yijun Shi, Long‐Sen Chang · 2020 · Biochemical Pharmacology
  6. Loss of SUV420H2 promotes EGFR inhibitor resistance in NSCLC through upregulation of MET via LINC01510
    A.S. Pal, Alejandra Agredo, Nadia A. Lanman, Jenna Clingerman, Kayla Gates, Andrea L. Kasinski · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  7. Reversible therapeutic resistance in EGFR mutant lung cancer caused by RB1 loss induced lineage plasticity
    Letian Zhang, Meenalakshmi Chinnam, Bradley Balk, Xiaojing Zhang, Yanqing Wang, Tatiana Shaurova, Shamshad Alam, Saraswati Pokharel, Prashant Singh, Justine J. Jacobi et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  8. Molecular Mechanisms of Acquired Therapeutic Resistance to Tyrosine Kinase Targeted Therapy
    Liwu Fu, Min Luo · 2025 · Cancer drug discovery and develogment/Cancer drug discovery and development
  9. Repurposing Mercaptopurine Through Collateral Lethality to Treat Cancers with Somatic RB1–NUDT15 Loss
    Tao Zhou, Huayun Yan, Dandan Yin, Yun Kai Deng, Huancheng Fu, Zichen Zhao, S. Li, Xiaoxi Lu, Yiqi Deng, Hai‐Ning Chen et al. · 2025 · MedComm
  10. Cell Cycle Plasticity and Heterogeneity: An Underappreciated Feature of Cancer and Treatment Response
    Erik S. Knudsen, Thomas N. O’Connor, Agnieszka Katarzyna Witkiewicz · 2025 · Cancer Heterogeneity and Plasticity
  11. Small cell lung cancer transdifferentiation: not a negligible phenomenon
    Lilla Horváth, Kristiina Boettiger, Zsolt Megyesfalvi, Balázs Döme, Clemens Aigner, Anita Horváth-Rózsás, Judit Berta · 2025 · Current Opinion in Oncology
  12. Clinicopathologic features and therapeutic outcomes in EGFR/ALK-aberrations NSCLC with histologic transformation
    Kaibo Ding, Xinyue Li, H Z Li, J. Qin, Dujiang Liu, Y. Xu · 2025 · Journal of Translational Medicine
  13. Case Report: Olaparib combined with temozolomide and atezolizumab in a case of BRCA2-mutated small-cell transformation of lung adenocarcinoma
    Meiyuan Liu, Pei Gao, Fu Liu, Deng Li, Yanqi Wang, Juan Yu · 2026 · Frontiers in Oncology
  14. Stem cell control in the lung by an autocrine injury-activated Igf complex
    Yue Zhang, Youcef Ouadah, Yin Liu, Maya E. Kumar, Makenna M. Morck, Mark A. Krasnow · 2026 · Science
  15. Targeting MET in 2025: From Exon 14 Skipping to MET-Amplified Acquired Resistance in Non-Small Cell Lung Cancer
    Aliya Khan, Michael Imeh, Priyanka Barad, Daniel Rosas · 2026 · International Journal of Molecular Sciences
  16. Transformation of NSCLC to SCLC: Insights into Molecular Alterations, Tumor Origin, and Therapeutic Advancements
    Anuska Mukherjee, Goutam Mukherjee, Subhadeep Das · 2026 · Onco
  17. ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report
    Huihui Li, Tianqi Song, Xiaoling Xu · 2023 · JTO Clinical and Research Reports
  18. Transdifferentiation of cervical squamous cell carcinoma with ERBB2 amplification to adenocarcinoma: whole genome sequence analysis and successful control by anti-HER2 therapy
    Hiroaki Ikushima, Kiyoshi Yamaguchi, Yoichi Furukawa, Seiya Imoto, Hirotomo Koda, Takuro Mizukami, Teppei Morikawa, Keita Uchino · 2023 · BJC Reports
  19. Rare case report: a case of histological type transformation of lung cancer caused by neoadjuvant immunotherapy
    Quanqing Li, Guangxin Zhang, Hao Yang, Jindong Li · 2024 · Frontiers in Oncology
  20. Case report: Personalized management of treatment resistance in advanced NSCLC patients with mutated epidermal growth factor receptor: special examples and literature review
    Jun Wang, Xiaojing Li, Shuang Dong, Sheng Hu, Fengming Ran, Yu Qian · 2025 · Frontiers in Oncology
  21. Partial transformation from non-small cell lung cancer to small cell lung cancer: a case report and literatures review
    Yicong Lu, Danruo Fang, Jiangying Guo, Huaqiong Huang · 2025 · Frontiers in Oncology
  22. Case Report: Transforming small cell lung cancer: two cases report and literature review
    Jinlong Liu, Jing Ai, Lize Zhao, Yimeng Qian, Qingxin Zhao, Chunling Ma, Yu Zhao, Jing Zhao · 2025 · Frontiers in Oncology
  23. Small cell lung cancer differentiation in patients with driver mutant non-small cell lung cancer: a single center experience
    Oğuzhan Yıldız, Melek Karakurt Eryılmaz, Ali Fuat Gürbüz, Bahattin Engin Kaya, Talat Aykut, Ömer Genç, Murat Araz, Mehmet Artaç · 2025 · Journal of Cancer Research and Clinical Oncology
  24. Temporospatial heterogeneity of acquired resistance mechanisms in EGFR-mutant lung adenocarcinoma: A case of concurrent EGFR mutation and small cell transformation
    Daniel Johnathan Hughes, Gary Cook, Emma McLean, Daniel Smith, Juliet Elizabeth King, Αθανάσιος Διαμαντόπουλος, Aled Jones, Michael J. Neat, George Santis, James F. Spicer et al. · 2021 · Current Problems in Cancer Case Reports
  25. Sequential small cell transformation and T790M mutation in an epidermal growth factor‐mutant lung adenocarcinoma: A rare occurrence with significant management implications
    Malvika Shastri, Parikshaa Gupta, Nalini Gupta, Navneet Singh, Amanjit Bal, Radhika Srinivasan, Divya Khosla · 2022 · Cytopathology
  26. Targeted Therapy und Precision Medicine
    David Felix Heigener, M. Horn, Martin Reck · 2016 · Der Internist
  27. Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma
    Jinyan Liang, Fan Tong, Feifei Gu, Yang-Yang Liu, Yulan Zeng, Xiao-Hua Hong, Kai Zhang, Li Liu · 2017 · Medicine
  28. Intratumoral heterogeneity and biomarkers for transformation into small cell lung carcinomas from lung adenocarcinomas
    Hyun Jung Lee, Sang‐Won Um · 2017 · Journal of Thoracic Disease
  29. Strategien zur Überwindung der erworbenen EGFR-TKI-Resistenz durch T790M spezifische Substanzen am Beispiel von Osimertinib
    Frank Griesinger, S. Radke, A Lüers, Barbara Deschler-Baier, Martin Kimmich, Martin Sebastian, Christian Klaus Jochen Schulz, Wolfram Brugger, Rainer Gerhard Wiewrodt, Robert Pirker et al. · 2018 · Pneumologie
  30. Cancer Genomics
    Elaine R. Mardis · 2015 · F1000Research
  31. A rotamer relay information system in the epidermal growth factor receptor–drug complexes reveals clues to new paradigm in protein conformational change
    Tareq Hameduh, Michal Mokry, Andrew David Miller, Vojtěch Adam, Zbyněk Heger, Yazan Haddad · 2021 · Computational and Structural Biotechnology Journal
  32. Endocrine secretory granule production is caused by a lack of REST and intragranular secretory content and accelerated by PROX1
    Jun Ishii, Hanako Sato‐Yazawa, Korehito Kashiwagi, Kazuhiko Nakadate, M. Iwamoto, Kakeru Kohno, Chie Miyata-Hiramatsu, Meitetsu Masawa, Masato Onozaki, Shuhei Noda et al. · 2022 · Journal of Molecular Histology
  33. [Two Cases of TKI-resistant Small Cell Lung Cancer Transformation in Advanced Adenocarcinoma and Literature Review].
    Jieqiong Wu, Dunqiang Ren, Bingqian Yi, Huanhuan Bi, Yanmei Shao, Hongmei Wang · 2022 · PubMed Central
  34. Targeting Metastatic Cancer: Disseminated Tumor Cells and Premetastatic Niches
    Anna Meiliana, Nurrani Mustika Dewi, Andi Wijaya · 2022 · The Indonesian Biomedical Journal
  35. Lung Tumors
    Helmut Popper · 2021 · Springer eBooks
  36. Résistances aux thérapeutiques ciblées et stratégies des lignes ultérieures dans les CBNPC métastatiques
    Solenn Brosseau, Youssef Oulkhouir, Charles Naltet, Gérard Zalcman · 2015 · Bulletin du Cancer
  37. Transformation of lung adenocarcinoma to small cell lung carcinoma in the setting of tyrosine kinase inhibitor therapy: Cytological approach of a clinically challenging phenomenon
    Siba El Hussein, Samer N. Khader · 2019 · Diagnostic Cytopathology
  38. Transformation from NSCLC to SCLC: when did it happen? – Authors' reply
    Jeffrey A. Engelman, Matthew G. Oser, Matthew J. Niederst, Lecia Van Dam Sequist · 2015 · The Lancet Oncology
  39. Role of CDK4/6 inhibitors in targeting Rb proficient small cell lung cancer
    Virginia Corbett, Triparna Sen, Aman Chauhan · 2024 · Translational Lung Cancer Research
  40. EED Maintains the Small Cell Lung Cancer Neuroendocrine Phenotype and Drives Lung Cancer Histological Transformation
    Yixiang Li, Yasmin Nabil Laimon, Hyeonseo Cho, Marina Vivero, Gabriel Roberti De Oliveira, Andrew Delcea, Varunika Savla, Yuting Chen, Yavuz T. Durmaz, Xintao Qiu et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  41. Depiction of neuroendocrine features associated with immunotherapy response using a novel one-class predictor in lung adenocarcinoma
    Hao Liu, Yan Han, Zhantao Liu, Liping Gao, Tienan Yi, Yuandong Yu, Yu Wang, Ping Qu, Longchao Xiang, Yong Li · 2023 · Discover Oncology
  42. Combination of Cytologic Findings and Circulating Tumor DNA From Cerebrospinal Fluid Revealed SCLC Transformation in Patients With Leptomeningeal Metastases of Lung Adenocarcinoma
    Jia-Xin Lin, Kai Yin, Li‐Xu Yan, Mei-Mei Zheng, Yang-Si Li, Shiling Zhang, Kang-Hui Zeng, Hong‐Hong Yan, Hai‐Yan Tu, Zhihong Chen et al. · 2024 · JTO Clinical and Research Reports
  43. Disease Course and Treatment Outcomes in Patients With De Novo Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 20 Insertion: Two Case Reports
    Lodovica Zullo, Elora Castanet, Zineb Maaradji, Maria‐Rosa Ghigna, Benjamin Bonhomme, Mélissa Alamé, Benjamin Besse, Sophie Cousin, Mihaela D. Aldea · 2024 · JCO Precision Oncology
  44. Molecular Characteristics, Heterogeneity, Plasticity, and Cell of Origin of Neuroendocrine Bladder Cancer
    Dongbo Xu, Qiang Li · 2025 · Cancer Heterogeneity and Plasticity
  45. Postoperative gastric cancer accompanied by large-cell neuroendocrine carcinoma: A case report
    Zhiqin Chen, Jiang Liu, Jin Liu, Yinhang Wu, Jian Liu · 2025 · Medicine
  46. First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From ALK-Rearranged NSCLC: Case Report
    Kaiwen Wang, Ceylan Altintas Taslic, Patricia de Groot, Mitchell A. Parma, Alvaro Guimaraes Paula, Melody Caranto, Komal Shah, Mukulika Bose, Cole Ruoff, Loukia Georgiou Karacosta et al. · 2025 · JTO Clinical and Research Reports
  47. Lineage plasticity: a new dilemma in lung cancer treatment
    Cainan Huo, Yongxuan Wang, Rujia Li, Xiaofei Xie, Weiqi Lyu, Dingke Chen, Yanqin Sun · 2026 · Molecular Biology Reports
  48. Dissecting histological transformation
    Ethan M. Earlie, Eric E. Gardner, HAROLD E. VARMUS, Ashley Marie Laughney · 2026 · Trends in cancer
  49. The evolving landscape of first-line and subsequent therapies in EGFR-mutated NSCLC: efficacy, resistance, and tolerability
    Carminia Maria Della Corte, Caterina De Rosa, Faiz Ul Haq, Floriana Morgillo · 2026 · Exploration of Targeted Anti-tumor Therapy
  50. Exploring PDLIM2 as a prognostic biomarker and therapeutic target in lung adenocarcinoma
    Karam Ashouri, Fan Sun, Harris Benjamin Krause, Andrew Elliott, Stephen V. Liu, Patrick C. Ma, Balázs Halmos, Gutian Xiao, Ari VanderWalde, Jorge J. Nieva et al. · 2026 · British Journal of Cancer
  51. Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance
    Nicolas Mathey‐Andrews, Carrie L. Rodriguez, Bing Shui, Agata L. Patriotis, William M. Rideout, Victor Z. Chen, Ileana Murazzi, Phaedra Ghazi, Milton R. Cornwall-Brady, Manyuan Liu et al. · 2026 · Nature Genetics
  52. Stratification in advanced non-small cell lung cancer: precision medicine in practice
    Odd Terje Brustugun · 2016 · Expert Review of Precision Medicine and Drug Development
  53. A Case of Lung Adenocarcinoma That Transformed to Small Cell Carcinoma During Gefitinib Therapy
    Chihiro Torigoe, Takuya Ueno, Suehiro Nishio, Toshiyuki Sawabe, Tokujiro Yano · 2017 · Haigan
  54. Anaplastic Lymphoma Kinase
    Nicolas A. Villanueva, Nicholas Giustini, Lyudmila A. Bazhenova · 2019 · Current cancer research
  55. Molecular basis of heterogeneity in small cell lung cancer
    Yuki Tenjin · 2022 · Translational Cancer Research
  56. Molecular Profiling and Data Analysis of Lung Adenocarcinoma
    Madhura Das, Uma Kumari · 2023 · International Journal for Research in Applied Science and Engineering Technology
  57. A challenging case of stage IV EGFR-mutant lung cancer with histologic transformation and multiple resistance mechanisms
    Joel Rivera‐Concepción, Ying‐Chun Lo, Dipesh Uprety, Alex A. Adjei, Vinicius Ernani, Konstantinos Leventakos · 2024 · Current Problems in Cancer Case Reports
  58. Transdifferentiation of metastatic melanoma into cerebellar angiosarcoma
    Nicolas Kostelecky, Nitin R. Wadhwani, Ivana Golubovich, Erica R Vormittag-Nocito, Juehua Gao, Lawrence J. Jennings, Michael Caron, Pouya Jamshidi, Jared T. Ahrendsen, Rudolph J. Castellani et al. · 2024 · Journal of Neuropathology & Experimental Neurology
  59. Unusual response with tyrosine kinase inhibitor in small-cell lung cancer
    Aashita, Hemendra Mishra, Kapil Suri, Vikas Yadav, Pragyat Thakur · 2024 · Annals of Oncology Research and Therapy
  60. Clinical and genetic characterization of a progressive RBL2-associated neurodevelopmental disorder
    Gabriel Aughey, Elisa Calì, Reza Maroofian, Maha Saad Zaki, Alistair T. Pagnamenta, Zafar Ali, Uzma Abdulllah, Fatima Rahman, Lara A. Menzies, Anum Shafique et al. · 2024 · Brain
  61. Case report: Anlotinib plus oral etoposide: a potential salvage therapy based on insights from EGFR-TKI-resistant SCLC transformation PDX and clinical settings
    Zixi Wang, Xiaoyu Li, Lili Jiang, Weiya Wang, Kai Xiao, Ting Zhang, Li Li, Dan Li, Yongsheng Wang · 2025 · Frontiers in Oncology
  62. [Advances in the Transformation to Small Cell Lung Cancer from Non-small Cell Lung Cancer Following Acquired Drug-resistance to EGFR Tyrosine Kinase Inhibitors].
    Wenqiu Zhang, Yongqi Li, Di Wu · 2017 · Europe PMC (PubMed Central)
  63. ASO Author Reflections: Genetic and Immunohistochemical Studies Investigating the Histogenesis of Neuroendocrine and Carcinomatous Components of Combined Neuroendocrine Carcinoma
    Misaki Iijima, Takehiko Yokobori, Akira Mogi, Ken Shirabe, Hiroyuki Kuwano · 2019 · Annals of Surgical Oncology
  64. [Mechanism of Histologic Transformation of Drive Gene Positive Lung Adenocarcinoma in Targeted Therapy and Treatment Strategy].
    Tongji Xie, Yan Li, Puyuan Xing · 2020 · PubMed Central
  65. Severe hyponatremia due to paraneoplastic syndrome of inappropriate antidiuretic hormone secretion in non-small cell lung carcinoma transforming to small cell lung carcinoma during treatment with immune checkpoint inhibitor
    Vicky Mai, Sylvain Trahan, Sylvain Pagé, Mathieu Simon, Catherine Labbé · 2021 · Current Problems in Cancer Case Reports
  66. Complete Remission to Afatinib in a Patient Harboring a Novel Epidermal Growth Factor Mutation in De Novo Small-Cell Lung Cancer: A Case Report
    Maximilian Johannes Hochmair, Oliver Illini, Helmut Prosch, Dagmar Krenbek, Arschang Valipour · 2021 · Clinical Lung Cancer
  67. Three Cases of EGFR-mutated Lung Cancer That Transformed to Small Cell Lung Cancer
    Daisuke Morinaga, Jun Sakakibara, Megumi Furuta, Naofumi Shinagawa, Tomohiro Goda, Kento Wakabayashi, Emi Takakuwa, Taichi Takashina, Satoshi Konno · 2022 · Haigan
  68. EGFR-Directed Therapy in Lung Cancer
    So Yeon Kim, Daniel Botelho Costa, Daisuke Shibahara, Susumu S. Kobayashi, Balázs Halmos · 2023 · Cambridge University Press eBooks
  69. Cellular heterogeneity–adjusted clonal methylation (CHALM) provides better prediction of gene expression
    Jianfeng Xu, Jiejun Shi, Xiaodong Cui, Ya Cui, Jingyi Jessica Li, Ajay Goel, Xi Chen, Jianzhong Su, Jean‐Pierre J. Issa, Wei Li · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  70. Faculty Opinions recommendation of EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
    Jean Clairambault · 2020 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  71. Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer
    Xi Ding, Minxing Shi, Di Liu, Jingxue Cao, Kaixuan Zhang, Rundong Zhang, Liping Zhang, Kaixing Ai, Bo Su, Jie Zhang · 2022 · Research Square
  72. Mechanisms of IKBKE Activation in Cancer
    Sridevi Challa · 2017 · Digital Commons - University of South Florida (University of South Florida)
  73. Faculty Opinions recommendation of Are there multiple cells of origin of Merkel cell carcinoma?
    Paul Nghiem · 2018 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  74. Targeting the Cell Surfaceome of Aggressive Neuroendocrine Prostate Cancer
    John K. Lee · 2018
  75. The mechanisms of acquired resistance to anti-EGFR drugs in non-small cell lung cancer not associated with T790m mutation and their significance in clinical practice
    Е. В. Карабина, Ludmila N. Lubchenko, М. М. Давыдов · 2018 · Advances in molecular oncology
  76. Les addictions oncogéniques : du diagnostic au suivi
    Michèle Beau‐Faller, Damien Reita, Véronique Lindner, M. Legrain, A. Schneider, Éric Guérin, Erwan Pencreach · 2018 · Revue des Maladies Respiratoires Actualités
  77. Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
    Nicolas Marcoux, Lecia Van Dam Sequist · 2018 · Elsevier eBooks
  78. Overcoming the drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancer cell lines
    Zhongwei Liu · 2018 · ThinkTech (Texas Tech University)
  79. The evolution of views on the possibilities of drug therapy in overcoming acquired resistance not associated with Т790М mutation to anti-EGFR drugs in non-small cell lung cancer
    Е. В. Карабина, Ludmila N. Lubchenko, A. N. Garunov · 2018 · Journal of Modern Oncology
  80. Retinoblastoma co-repressor 1 (RB) and cyclin-dependent kinase inhibitor (CDKN) as a multi-gene panel for differentiating pulmonary from non-pulmonary origin in metastatic neuroendocrine carcinomas
    Kritika Krishnamurthy, Mike Cusnir, Michael Schwartz, Vathany Sriganeshan, Robert Poppiti · 2020 · Pathology - Research and Practice
  81. Transformacja gruczołowego raka płuca w raka drobnokomórkowego u pacjentki leczonej inhibitorem kinazy receptora dla naskórkowego czynnika wzrostu – opis przypadku.
    Monika Misztal, Magdalena Krakowska, Mariusz Śliwa, Piotr Potemski · 2020 · Oncology in Clinical Practice
  82. FoxA1 and FoxA2 regulate growth and cellular identity in NKX2-1-positive lung adenocarcinoma
    Grace Orstad, Gabriela Fort, Timothy J. Parnell, Alex D. Jones, Chris Stubben, Brian K. Lohman, Katherine L. Gillis, Walter A. Orellana, Rushmeen Tariq, Olaf Klingbeil et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  83. Bruceine D and Afatinib Combination Inhibits Ovarian Cancer Cells Proliferation and Migration Through DNA Damage Repair and EGFR Pathway
    Feng Lin, Jufan Zhu, Luo Wang, Yuanjun Yang, Ru-ru Zheng, Xu Zhang, Yan Hu · 2021 · Research Square
  84. Sequential occurrence of T790M mutation and small cell lung cancer transformation in EGFR-positive lung adenocarcinoma: A case report
    Er Hong, Xi-Er Chen, Jia Mao, Jingjing Zhou, Ling Chen, Jia-Yi Xu, Wei Tao · 2022 · World Journal of Clinical Cases
  85. Clinical decision support system to predict the efficacy for EGFR-TKIs based on artificial neural network
    Xiao Liang, Runwei Guan, Jiamin Zhu, Yue Meng, Jing Zhu, Yuxiang Yang, Yanan Cui, Jiali Dai, Jun Shao, Weidong Mao et al. · 2022 · Research Square
  86. Faculty Opinions recommendation of Intertumoral heterogeneity in SCLC is influenced by the cell type of origin.
    Kent W. Hunter · 2018 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  87. Pulmonary Large Cell Neuroendocrine Carcinoma
    B.C.M. Hermans · 2021
  88. Neuroendokrines Prostatakarzinom
    Verena‐Wilbeth Sailer, Sven Perner · 2020 · Springer eBooks
  89. Research Progress of Acquired EGFR-TKI Resistance in Patients with Advanced Lung Adenocarcinoma
    康 王 · 2021 · Advances in Clinical Medicine
  90. Liquid Biopsy as an Option for Predictive Testing and Prognosis in Patients with Lung Cancer
    Alvida Qvick, Bianca Stenmark, Jessica Carlsson, Johan Isaksson, Christina Karlsson, Gisela Helenius · 2021 · Research Square
  91. EGFR T790M Site-Mutated Non-Small Cell Lung Cancer Drug Resistance Mechanism and Comprehensive Treatment after Drug Resistance
    卉淇 武 · 2022 · Advances in Clinical Medicine
  92. Cancer of the Lung
    Daniel Morgensztern, Daniel J. Boffa, Alexander Junxiang Chen, Andrew P. Dhanasopon, Sarah B. Goldberg, Roy H. Decker, Siddhartha H. K. Devarakonda, Jane P. Ko, Luisa M. Solis Soto, Saiama Naheed Waqar et al. · 2022 · Wiley eBooks
  93. Data from Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer
    Kota Ishioka, Hiroyuki Yasuda, Junko Hamamoto, Hideki Terai, Katsura Emoto, Tae Jung Kim, Shigemichi Hirose, Takashi Kamatani, Sachiyo Mimaki, Daisuke Arai et al. · 2023
  94. Clinical characteristics and gene mutation analysis of patients with transformed small-cell lung cancer
    Jiayong Qiu, Yingying Hao, Shenshen Huang, Yingwei Zhu, Tongsheng Wang, Yimin Mao, Yadong Yuan · 2023 · Research Square
  95. Data from Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation
    Smruthy Sivakumar, Jay A. Moore, Meagan Montesion, Radwa Raed Sharaf, Douglas I. Lin, Caterina I. Colón, Zoë Fleischmann, Ericka M. Ebot, Justin Y. Newberg, Jennifer M. Mills et al. · 2023
  96. Potential of Heterocyclic Compounds as EGFR-TK Inhibitors in Cancer Therapy
    Aniket P. Sarkate, Shashikant V. Bhandari, Poonam R. Inamdar, Pranali Vijaykumar Kuthe, Kalusing S. Padvi · 2023 · Springer eBooks
  97. Clinical and neurogenetic characterisation of autosomal recessive RBL2-associated progressive neurodevelopmental disorder
    Gabriel Aughey, Elisa Calì, Reza Maroofian, Maha Saad Zaki, Alistair T. Pagnamenta, Fatima Rahman, Lara A. Menzies, Anum Shafique, Mohnish Suri, Emmanuel Flamand Roze et al. · 2024 · medRxiv
  98. Integrating Multi-Omics Analysis and Machine Learning to Identify Molecular Subtypes and Construct Prognostic Models for Lung Squamous Cell Carcinoma
    Ya Dong, Xiang Zhang, Yuhan Wang, Tao Xu · 2024 · Research Square
  99. Personalized Molecular Therapies for Advanced Non-Small Cell Lung Cancer: Overcoming Heterogeneity to Optimize Treatment Response and Clinical Outcomes
    Zuan-Fu Lim · 2024
  100. ARAF Amplification in Small-Cell Lung Cancer-Transformed Tumors Following Resistance to Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors
    Ryo Kimura, Yuta Adachi, Kentaro Hirade, Satoru Kisoda, Shogo Yanase, Noriko Shibata, Makoto Ishii, Yutaka Fujiwara, Rui Yamaguchi, Yasuko Fujita et al. · 2024 · Cancers